Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
184 participants
INTERVENTIONAL
2003-12-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunotherapy of Stage III/IV Melanoma Patients
NCT00112242
IMCgp100 in Advanced Unresectable Melanoma
NCT01209676
Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
NCT00145145
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
NCT00112229
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
NCT00019890
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CPG 7909 Injection plus chemotherapy
CPG 7909 Injection plus DTIC
CPG 7909 Injection
CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
dacarbazine
dacarbazine 850mg/m2 in three-week cycles until disease progression
Chemotherapy alone
dacarbazine
Chemotherapy
Chemotherapy in three-week cycles until disease progression:
dacarbazine 850mg/m2
CPG 7909 Injection 10 mg
CPG 7909 Injection
CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
CPG 7909 Injection 40 mg
CPG 7909 Injection
CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CPG 7909 Injection
CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
dacarbazine
dacarbazine 850mg/m2 in three-week cycles until disease progression
Chemotherapy
Chemotherapy in three-week cycles until disease progression:
dacarbazine 850mg/m2
CPG 7909 Injection
CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
CPG 7909 Injection
CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Measurable disease according to the RECIST criteria.
* Karnofsky Performance Status of \> 70.
Exclusion Criteria
* Suspected or known CNS metastases.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CO23, A8501023
Identifier Type: -
Identifier Source: secondary_id
C023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.